CD8A and neoplasm: Recent evidence indicates that type 1 IFN plays an important role in many anticancer modalities, including immunotherapy, helping to promote dendritic cell activation and prime and recruit cytotoxic CD8+ T-cells against tumor-associated antigens [133,134,135].